Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026

Rhea-AI Summary

Standard BioTools (NASDAQ: LAB) will report its first quarter 2026 financial results on May 5, 2026, to be released after the U.S. market close.

Investors can expect a post-close release and likely an accompanying conference call or investor materials referenced by the company.

News Market Reaction – LAB

-1.00%

9 alerts

-1.00% Session close to close

+3.2% Peak Tracked

-9.3% Trough Tracked

$405.64M Market Cap

0.5x Rel. Volume

In the Apr 21 session, LAB declined 1.00%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.2% during that session. Argus tracked a trough of -9.3% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timing for Standard BioTools’ Q1 2026 results on May 5, 2026 after U.S. m...

Analysis

This announcement sets the timing for Standard BioTools’ Q1 2026 results on May 5, 2026 after U.S. market close, continuing its regular earnings communication cadence. Historically, an earlier earnings date notice produced only a modest -1.59% move, suggesting such scheduling updates have not been major catalysts. Investors may focus next on how Q1 results compare with prior guidance and recent restructuring progress.

Previous Earnings date Reports

1 past event · Latest: Feb 10 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 10	Earnings date announcement	Neutral	-1.6%	Set timing for Q4 and full-year 2025 results release after market close.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings date communication saw a modest move of -1.59%, suggesting earnings timing headlines have historically triggered limited price reaction.

Recent Company History

Over recent months, Standard BioTools has combined restructuring and portfolio changes with regular financial communications. A prior earnings date notice on Feb 10, 2026 coincided with a modest -1.59% move. Subsequent results on Feb 24, 2026 highlighted $23.8M Q4 revenue and $85.3M full-year 2025 revenue, alongside significant cost savings and a strong cash position. The latest announcement of the Q1 2026 results date continues this cadence of scheduled updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close.

About Standard BioTools Inc.

Standard BioTools Inc. (NASDAQ: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook^®, LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/.
Patent and License Information: standardbio.com/legal/notices.
©2026 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com

FAQ

When will Standard BioTools (LAB) release Q1 2026 results?

Standard BioTools will publish its Q1 2026 results on May 5, 2026 after U.S. market close. According to the company, the timing allows investors to review the release and any supplemental materials before the next trading day.

How can investors access Standard BioTools (LAB) Q1 2026 financial results on May 5, 2026?

Investors can access the results via the company's investor relations page and SEC filings after the close. According to the company, the release will be posted online and may include financial tables and a press statement.

Will Standard BioTools (LAB) hold a conference call for the May 5, 2026 earnings release?

The company has not specified a call in this announcement; the primary notice covers the release timing. According to the company, any webcast or call details typically follow the earnings release or investor relations notice.

What time should traders expect Standard BioTools (LAB) Q1 2026 results on May 5, 2026?

Results are expected after the U.S. market close on May 5, 2026, typically after 4:00 PM ET. According to the company, the exact posting will occur following market close and will be available online.

Will Standard BioTools (LAB) provide accompanying financial tables with the May 5, 2026 release?

The announcement indicates a standard quarterly release schedule but does not list attachments. According to the company, detailed financial tables and metrics are commonly included with quarterly results releases.

How should investors prepare for Standard BioTools (LAB) Q1 2026 results on May 5, 2026?

Investors should plan to review the post-close release and any follow-up webcast or filing the next morning. According to the company, monitoring the investor relations site will provide official materials and timing updates.